Cargando…
Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor
B-cell activating factor (BAFF) is a B-cell survival factor with a key role in B-cell homeostasis and tolerance. Dysregulated BAFF expression may contribute to autoimmune diseases or B-cell malignancies via effects on abnormal B-lymphocyte activation, proliferation, survival, and immunoglobulin secr...
Autores principales: | Manetta, Joseph, Bina, Holly, Ryan, Paul, Fox, Niles, Witcher, Derrick R, Kikly, Kristine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4173659/ https://www.ncbi.nlm.nih.gov/pubmed/25258549 http://dx.doi.org/10.2147/JIR.S67751 |
Ejemplares similares
-
Discovery and characterization of a neutralizing pan-ELR+CXC chemokine monoclonal antibody
por: Boyles, Jeffrey S., et al.
Publicado: (2020) -
Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A
por: Liu, Ling, et al.
Publicado: (2016) -
Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2016) -
A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell–activating factor monoclonal antibody, for rheumatoid arthritis
por: Greenwald, Maria, et al.
Publicado: (2014) -
Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study
por: Schiff, Michael, et al.
Publicado: (2015)